Skip to main content Back to Top


Multiple Vitamins for Infusion

Products Affected - Description

    • Infuvite injection, Baxter, Adult, 2 x 5 mL single dose vial, 100 count, NDC 05464-3564-91
    • Infuvite injection, Baxter, Adult, 2 x 50 mL bulk vial, 10 count, NDC 05464-3565-02
    • Infuvite injection, Baxter, Pediatric, 5 mL single dose vial, 100 count, NDC 05464-3564-61
    • Infuvite injection, Baxter, Pediatric, 50 mL bulk vial, 1 count, NDC 05464-3564-70
    • Multivitamin for infusion (MVI) Adult, Pfizer, MVI Adult, 2 x 5 mL Dual vial, 1 count, NDC 61703-0434-82 - discontinued
    • Multivitamin for infusion (MVI) Adult, Pfizer, MVI Adult, 2 x 50 mL Dual vial, 10 count, NDC 61703-0422-83 - discontinued
    • Multivitamin for infusion (MVI) Pediatric, Pfizer, MVI Pediatric, 5 mL vial, 10 count, NDC 61703-0421-53 - discontinued

Reason for the Shortage

    • Baxter has Infuvite on shortage due to 3rd party supplier manufacturing delays.
    • Pfizer discontinued M.V.I. presentations in October 2021.

Available Products

    • There is insufficient supply for usual ordering

Estimated Resupply Dates

    • Baxter has Adult Infuvite 10 mL vials and Pediatric Infuvite 5 mL vials on allocation. The Adult Infuvite 100 mL vials and Pediatric Infuvite 50 mL vials are on back order and the company cannot estimate a release date.

Alternative Agents & Management

    • The American Society for Parenteral and Enteral Nutrition (ASPEN) has detailed recommendations for managing an intravenous multivitamin shortage in adults and pediatric patients:
    • Key recommendations include:
    • Use oral or enteral multivitamin preparations whenever possible.
    • Use of pediatric intravenous multivitamins for adults is not recommended and may result in a shortage of pediatric products.
    • Use of multivitamin preparations without vitamin K is fine with individual supplementation of Vitamin K products. Ensure patients receiving vitamin K are getting adequate anticoagulation if they are on warfarin.
    • Reserve intravenous multivitamins for patients receiving parenteral nutrition.
    • Reserve pediatric intravenous multivitamins for children less than 2.5 kg or less than 36 weeks gestational age. Consider using 5 mL of adult intravenous multivitamins in children weighing greater than or equal to 2.5 kg or gestational age of 36 weeks or older. Supplement intravenous vitamin K (total daily dose = 200 mcg).
    • If no pediatric intravenous multivitamins are available, infants less than 2.5 kg or less than 36 weeks gestation should receive adult intravenous multivitamin at a daily dose of 1 mL/kg up to a maximum of 2.5 mL per day. Supplement intravenous vitamin K daily (total daily dose = 200 mcg).
    • When all supply options are exhausted, ration intravenous multivitamins in parenteral nutrition or administer individual parenteral vitamins.
    • Purchase only the supply needed, do not stockpile.
    • Use oral products when appropriate, however review the oral product to ensure it contains sufficient amounts of essential vitamins (eg, folate, thiamine). Oral vitamin products are considered dietary supplements and are not approved by FDA. Availability and contents of these products varies widely. Components can change at any time.


Updated October 30, 2022 by Michelle Wheeler, PharmD, Drug Information Specialist. Created June 23, 2008 by Jane Chandramouli, PharmD, Drug Information Specialist. © 2022, Drug Information Service, University of Utah, Salt Lake City, UT.



Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.